title: The prostaglandin agonist beraprost aggravates doxorubicin-mediated apoptosis by increasing iNOS expression in cardiomyocytes.
abstract: Doxorubicin (DOX) is widely used as an anti-cancer agent although it causes irreversible cardiomyopathy by increasing oxidative stress and deregulating nitric oxide production. Beraprost (BPS), a stable prostacyclin (PGI2) analog, is a potent vasodilator that has beneficial effects on myocardial ischemia. The objectives of the present study were to delineate the uncertain effects of prostcyclin therapy on DOX induced cardiomyopathy and to explore the mechanisms underlying PGI2 and DOX interaction. For this reason, we stimulated endogenous PGI2 production using bicistronic COX-1/PGIS gene transfer and BPS supplementation, and investigated the effects on DOX-induced cardiomyopathy. Caspase-dependent protein content, lactate dehydrogenase (LDH), DNA fragmentation, and TUNEL positive cells were elevated in DOX-treated cardiomyocytes. These indicators were further elevated by adenovirus-COX- 1/PGIS transfection or BPS supplementation. In addition, PGI2 overexpression further increased iNOS expression and superoxide accumulation in cardiomyocytes compared with DOX alone, which may be the reason for aggravated cytotoxicity. Moreover, BPS can induce cAMP response elements (CRE) binding to the iNOS promoter and phospho- cAMP response element binding protein (CREB) expression in a cyclic AMP-dependent manner. Our in vivo studies show that MnTBAP and aminoguanidine treatment of DOX and BPS co-administered in mice can attenuate caspase-3 and PARP-1 protein expression, and improve mouse survival, as observed in the iNOS gene-deleted mice. In conclusion, we demonstrated that BPS or adv-COX-1/PGIS increases PGI2 levels through iNOS expression and peroxynitrite production, via CREB protein phosphorylation; thereby aggravating DOX-mediated cardiotoxicity.
authors.forename: Wei-Shiung
authors.initials: WS
authors.lastname: Lian
authors.forename: Herng-Cheng
authors.initials: HC
authors.lastname: Chiou
authors.forename: Heng
authors.initials: H
authors.lastname: Lin
authors.forename: Jin-Jer
authors.initials: JJ
authors.lastname: Chen
authors.affiliation: Department of Medical Research, Tzu Chi General Hospital, 707, Sec 3, Chung Yang Road, 970 Hualien, Taiwan. cfcheng@ibms.sinica.edu.tw.
authors.forename: Ching-Feng
authors.initials: CF
authors.lastname: Cheng
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D050882:CREB-Binding Protein / Q000378:metabolism; D009202:Cardiomyopathies / Q000378:metabolism; D051545:Cyclooxygenase 1 / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology*; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017202:Myocardial Ischemia / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D030421:Peroxynitrous Acid / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011453:Prostaglandins / Q000819:agonists*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D011453:Prostaglandins; D030421:Peroxynitrous Acid; C048081:beraprost; D004317:Doxorubicin; D011464:Epoprostenol; D052247:Nitric Oxide Synthase Type II; D051545:Cyclooxygenase 1; D050882:CREB-Binding Protein